Inspire(US:INSP) Globenewswire·2026-01-02 19:04Core Viewpoint - A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) for allegedly misleading investors about operational failures related to the launch of its Inspire V device for obstructive sleep apnea [1][3]. Group 1: Lawsuit Details - The lawsuit claims that Inspire Medical and its executives assured investors of the company's "operational readiness" for the Inspire V launch, which was later revealed to be false due to undisclosed operational issues [3][4]. - The class period for the lawsuit includes investors who purchased INSP securities between August 6, 2024, and August 4, 2025 [2]. - The lead plaintiff deadline for the lawsuit is January 5, 2026, urging affected investors to contact the law firm Hagens Berman [3]. Group 2: Allegations of Concealment - Allegations include failures in Medicare claims processing software that delayed the rollout of the Inspire V device, impacting revenue generation [4]. - An excess inventory of the older Inspire IV device created a demand issue for the new Inspire V, leading to a significant cut in 2025 earnings per share (EPS) guidance by over 80% [4]. - Many treatment centers had not completed necessary training for the new device, contributing to a 32.4% decline in stock value, equating to a drop of $42.04 per share [4]. Group 3: Investigation Focus - Hagens Berman's investigation emphasizes the concealment of critical operational issues, particularly the Medicare claims software failure and the inventory surplus of the Inspire IV device [5]. - The firm asserts that the stock collapse was due to management prioritizing a narrative of a seamless transition over the actual operational challenges [5].